PF-Atlas › Clinical Trials › NCT00703339
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Treprostinil sodium for inhalation · Phase 2
Registry ID
NCT00703339
Phase
Phase 2
Status
Terminated
Drug / intervention
Treprostinil sodium for inhalation
Sponsor
Lung Biotechnology PBC
Start
2008-06
Enrollment
1
Locations
6
About this trial
The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a range of tolerable doses. The safety and pharmacodynamic information obtained from this study will inform the design and conduct of future studies in inhaled treprostinil sodium in this population.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00703339 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.